http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Fourth Ventricle Neurenteric Cyst Mimicking Hemangioblastoma
( Eugenie Choe ),( Kihwan Hwang ),( Gheeyoung Choe ),( Chae-yong Kim ) 대한뇌종양학회 대한신경종양학회 2017 Brain Tumor Research and Treatment Vol.5 No.1
This report presents a case of fourth ventricle neurenteric cyst (NE cyst) mimicking hemangioblastoma, which developed in a 50-year-old woman. A tiny enhancing mural portion of the fourth ventricle in MRI suggested that the cyst was hemangioblastoma, but pathological evidence showed that the cyst was in fact NE cyst in the fourth ventricle. In order to make proper decision on to what extent of surgical resection should be done, considering every possibility in differential diagnosis might be helpful. This case reports an unusual pathology in 4th ventricle, considering the patient`s age, and demonstrates that a rarer disease may share radiological features of a common disease.
Uwiragiye, Eugenie,Farooq, Muhammad Umer,Moon, Su-Hyun,Pham, Thuy Linh,Nguyen, Dang Thanh,Lee, Jong-Sook,Fisher, John G. Elsevier 2017 Journal of the European Ceramic Society Vol.37 No.15
<P><B>Abstract</B></P> <P>0.96(K<SUB>0.48</SUB>Na<SUB>0.52</SUB>)NbO<SUB>3</SUB>-0.03[Bi<SUB>0.5</SUB>(Na<SUB>0.7</SUB>K<SUB>0.2</SUB>Li<SUB>0.1</SUB>)<SUB>0.5</SUB>]ZrO<SUB>3</SUB>-0.01(Bi<SUB>0.5</SUB>Na<SUB>0.5</SUB>)TiO<SUB>3</SUB> single crystals were grown for the first time by the solid state crystal growth method, using [001] or [110]-oriented KTaO<SUB>3</SUB> seed crystals. The grown single crystal shows a dielectric constant of 2720 and polarization-electric field loops of a lossy normal ferroelectric, with P<SUB>r</SUB> =45μC/cm<SUP>2</SUP> and E<SUB>c</SUB> =14.9kV/cm, while the polycrystalline samples with a dielectric constant of 828 were too leaky for P-E measurement due to humidity effects. The single crystal has orthorhombic symmetry at room temperature. Dielectric permittivity peaks at 26°C and 311°C, respectively, are attributed to rhombohedral-orthorhombic and tetragonal–cubic phase transitions. Additionally, Raman scattering shows the presence of an orthorhombic-tetragonal phase transition at ∼150°C, which is not indicated in the permittivity curves but by the loss tangent anomalies. A transition around 700°C in the high temperature dc conductivity is suggested to be a ferroelastic-paraelastic transition.</P>
Choe, Eugenie,Lee, Tae Young,Kim, Minah,Hur, Ji-Won,Yoon, Youngwoo Bryan,Cho, Kang-Ik K.,Kwon, Jun Soo Elsevier 2018 SCHIZOPHRENIA RESEARCH Vol.199 No.-
<P><B>Abstract</B></P> <P><B>Introduction</B></P> <P>It has been suggested that the mentalizing network and the mirror neuron system network support important social cognitive processes that are impaired in schizophrenia. However, the integrity and interaction of these two networks have not been sufficiently studied, and their effects on social cognition in schizophrenia remain unclear.</P> <P><B>Methods</B></P> <P>Our study included 26 first-episode psychosis (FEP) patients and 26 healthy controls. We utilized resting-state functional connectivity to examine the a priori-defined mirror neuron system network and the mentalizing network and to assess the within- and between-network connectivities of the networks in FEP patients. We also assessed the correlation between resting-state functional connectivity measures and theory of mind performance.</P> <P><B>Results</B></P> <P>FEP patients showed altered within-network connectivity of the mirror neuron system network, and aberrant between-network connectivity between the mirror neuron system network and the mentalizing network. The within-network connectivity of the mirror neuron system network was noticeably correlated with theory of mind task performance in FEP patients.</P> <P><B>Conclusion</B></P> <P>The integrity and interaction of the mirror neuron system network and the mentalizing network may be altered during the early stages of psychosis. Additionally, this study suggests that alterations in the integrity of the mirror neuron system network are highly related to deficient theory of mind in schizophrenia, and this problem would be present from the early stage of psychosis.</P>
Association of DNA damage with vitamin D and hair heavy metals of obese women
Ng Chiat Yin,Amini Farahnaz,Ahmad Bustami Normina,Tan Eugenie Sin Sing,Tan Pui Yee,Mitra Soma Roy 대한독성 유전단백체 학회 2021 Molecular & cellular toxicology Vol.17 No.4
Background Obesity has been linked to DNA damage. The modifiable risk factors may modulate the impact of obesity on DNA damage. Objective This study aimed to assess DNA damage and its association with dietary nutrient, serum 25-hydroxyvitamin D (25(OH)D) and concentration of hair heavy metals of obese and non-obese women. Method A case–control study was conducted involving 134 women aged between 20 and 50 years. Serum 25(OH)D, fasting glucose, and lipid profile were assessed. Indicators of DNA damage such as percentage of tail DNA, tail moment, tail olive moment, tail intensity and tail length were measured using an alkaline-comet assay. Concentrations of hair heavy metals were quantified using inductively coupled plasma–mass spectrometry (ICP–MS). Participants' daily energy, macro, and micronutrient intake were collected using the Food Frequency Questionnaire. Results Mean values of serum 25(OH)D was 31.8 ± 0.9 nmol/L. 96.3% of participants were vitamin D deficiency (< 50 nmol/L). The mean BMI was 26.3 ± 0.5 kg/m2. Half of the participants (50.7%) have a high frequency of DNA strand breaks. Mean concentration of hair heavy metals (mg/kg) were 0.1 ± 0.03 (arsenic), 0.2 ± 0.1 (cadmium), 1.0 ± 0.4 (mercury), 2.8 ± 0.8 (lead),and 6.2 ± 0.4 (chromium). There was no significant difference for the mean of serum 25(OH)D, indicators of DNA damage, concentrations of hair heavy metals and dietary nutrients between obese and non-obese groups (p > 0.05). Obese women with serum 25(OH)D level of ≥ 31 nmol/L had a significantly lower tail moment (p = 0.029) and tail olive moment (p = 0.031); thus, indicating less DNA damage. Additionally, obese women with hair chromium concentration of ≥ 5.88 mg/kg had a significantly higher tail moment (p = 0.047), indicating more DNA damage. Conclusion DNA damage among obese women correlated with serum 25(OH)D and hair chromium. Background Obesity has been linked to DNA damage. The modifiable risk factors may modulate the impact of obesity on DNA damage. Objective This study aimed to assess DNA damage and its association with dietary nutrient, serum 25-hydroxyvitamin D (25(OH)D) and concentration of hair heavy metals of obese and non-obese women. Method A case–control study was conducted involving 134 women aged between 20 and 50 years. Serum 25(OH)D, fasting glucose, and lipid profile were assessed. Indicators of DNA damage such as percentage of tail DNA, tail moment, tail olive moment, tail intensity and tail length were measured using an alkaline-comet assay. Concentrations of hair heavy metals were quantified using inductively coupled plasma–mass spectrometry (ICP–MS). Participants' daily energy, macro, and micronutrient intake were collected using the Food Frequency Questionnaire. Results Mean values of serum 25(OH)D was 31.8 ± 0.9 nmol/L. 96.3% of participants were vitamin D deficiency (< 50 nmol/L). The mean BMI was 26.3 ± 0.5 kg/m2. Half of the participants (50.7%) have a high frequency of DNA strand breaks. Mean concentration of hair heavy metals (mg/kg) were 0.1 ± 0.03 (arsenic), 0.2 ± 0.1 (cadmium), 1.0 ± 0.4 (mercury), 2.8 ± 0.8 (lead),and 6.2 ± 0.4 (chromium). There was no significant difference for the mean of serum 25(OH)D, indicators of DNA damage, concentrations of hair heavy metals and dietary nutrients between obese and non-obese groups (p > 0.05). Obese women with serum 25(OH)D level of ≥ 31 nmol/L had a significantly lower tail moment (p = 0.029) and tail olive moment (p = 0.031); thus, indicating less DNA damage. Additionally, obese women with hair chromium concentration of ≥ 5.88 mg/kg had a significantly higher tail moment (p = 0.047), indicating more DNA damage. Conclusion DNA damage among obese women correlated with serum 25(OH)D and hair chromium.
Li Xiaotong,Liou Kevin T.,Susan Chimonas,Karolina Bryl,Wong Greta,Eugenie Spiguel,Susan Q. Li,Sheila N.Garland,Bao Ting,Mao Jun J 한국한의학연구원 2023 Integrative Medicine Research Vol.12 No.1
Background: Fatigue is a troublesome symptom in cancer survivors that often results from disrupted sleep. We sought to assess whether two insomnia-focused non-pharmacological interventions are also effective for improving fatigue. Methods: We analyzed data from a randomized clinical trial comparing cognitive behavioral therapy for insomnia (CBT-I) versus acupuncture for insomnia among cancer survivors. Participants were 109 patients who reported insomnia and moderate or worse fatigue. Interventions were delivered over eight weeks. Fatigue was evaluated at baseline, week 8, and week 20 using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF). We used both mediation analysis and t-tests to explore the extent to which fatigue reduction was attributable to insomnia response. Results: Compared to baseline, both CBT-I and acupuncture produced significant reductions in total MFSI- SF scores at week 8 ( −17.1 points; 95% confidence interval [CI]: −21.1 to −13.1, and −13.2 points; 95% CI: -17.2 to -9.2, respectively, all p < 0.001) and week 20 (-14.6 points; 95% CI: -18.6 to -10.6, and −14.2 points; 95% CI: -18.1 to -10.3. respectively, all p < 0.001), with no significant between-group differences. MFSI-SF total scores at week 8 were significantly associated with sleep improvements in both CBT-I and acupuncture groups ( p < 0.001 and p = 0.011, respectively). Insomnia responders demonstrated significantly greater improvements in mean MFSI-SF total scores compared with non-responders in the CBT-I group ( p = 0.016) but not in the acupuncture group. Conclusion: CBT-I and acupuncture produced similar, clinically meaningful, and durable fatigue reduc- tions in cancer survivors with insomnia, primarily through improvements in sleep. Acupuncture may also reduce fatigue through additional pathways. Trial registration: ClinicalTrials.gov, identifier: